BETHEL, Conn., Jan. 2 /PRNewswire-FirstCall/ -- Aduromed Industries, Inc. (OTC Bulletin Board: ADRM), a provider of innovative technology and services for the onsite treatment and disposal of regulated medical waste, today announced that it has become MedClean Technologies, Inc., marking the official launch of the Company's integrated business plan to emerge as the leader in the $2 billion market opportunity for onsite regulated medical waste (RMW) treatment at hospitals and other healthcare facilities. The Company will continue to trade under the ticker "ADRM" until further notice.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090102/LAF001LOGO)

"MedClean Technologies is the result of our efforts to create a break-out business model that makes it easy for healthcare institutions to embrace the Company's onsite solutions for RMW treatment and management, which help hospitals reduce expenses, mitigate risks, and protect the environment," said Scott Grisanti, President and Chief Executive Officer of MedClean.

MedClean Technologies leverages the Company's established technology with recent and future advancements and a new, customer-focused business model to deliver sophisticated, comprehensive and fully integrated on-demand solutions for the treatment and volume reduction of RMW and HIPAA-compliant destruction of confidential documents. These solutions are delivered in industry-standard containers that require no installation within an institution's facility, reducing the required footprint within a facility. The proprietary MedClean Container Series configuration, which is the subject of a patent filing, includes features that facilitate easy access to hospital utilities, in addition to options for on-board utilities in the event that electric and/or steam are not easily accessible. The MedClean Mobile Series adds transportability, allowing multi-site healthcare organizations to cost effectively leverage a system across several locations.

"To make MedClean's on-demand solutions accessible to more healthcare institutions, we have added a variety of acquisition options," said Mr. Grisanti. "In addition to traditional capital purchases, we have added lease and rental programs to match the demands of target customers and significantly expand the Company's overall market opportunity. A MedClean Container system can replace one or more trailers from off-site providers for RMW and confidential documents. In a similar manner, the expense for a MedClean Container rental can replace -- at a lower cost -- the expense for one or more off-site vendors."

Recent Developments

As part of the re-launch of the Company as MedClean Technologies, and particularly since the recapitalization in early August, the Company has completed several important initiatives and strengthened its competitive position. Initiatives include an augmented board of directors and new, professional management, as well as an application for a new patent to strengthen the Company's intellectual property position. Recent additions to the leadership team include:

-- The strengthening of the board of directors with the addition of Joseph Esposito (director and Chairman of the Board) and Kenneth Londoner (director).

-- The appointment of Scott Grisanti as President and CEO and a director of the Company.

-- The appointment of John R. Accardi as Senior VP of Sales and David J. Laky as Senior VP of Client Services, responsible for professional services, customer care, engineering and manufacturing.

"During the last six months, we have taken the necessary steps to develop a customer-focused business plan and deploy professional management and an experienced, shareholder-focused board of directors," Mr. Grisanti added. "Today, MedClean emerges a stronger organization with a proven leadership team in place poised to accelerate the execution of a differentiated business plan that capitalizes on a sustainable competitive advantage. I anticipate that our efforts over the past six months will produce visible results for our shareholders during 2009."

In addition to the MedClean Container configuration, the patent filing: "Containerized Medical Waste Treatment System and Related Method," also covers the treatment protocol used to achieve a superior level of RMW sterilization. A single MedClean Container system can treat 1 million pounds of RMW per year, in addition to handling confidential document destruction. The appropriate processing and destruction of confidential medical documents is an important consideration under federal HIPAA regulations.

"The intellectual property articulated in our patent filing provides a sustainable competitive advantage to MedClean Technologies and our customers," added Mr. Grisanti. "Combined with our system workflow, which minimizes handling of bio-hazardous waste by healthcare workers, MedClean systems mitigate risk by addressing 'cradle-to-grave' hospital responsibility for untreated RMW. Once treated, the volume of sterilized waste is reduced by 80 to 85%, which minimizes the carbon footprint of healthcare organizations, while onsite sterilization also eliminates the need to transport untreated RMW through host communities, an issue which currently represents a liability for hospitals.

"In short, the advanced MedClean system will lower expenses, reduce the environmental impact, and eliminate unnecessary risks for hospitals," concluded Mr. Grisanti. "These messages, along with our attractive pricing options, will resonate with cost and image-conscious healthcare organizations. We also believe the new model will enable us to target a far wider range of healthcare organizations, benefiting our shareholders and enabling us to scale revenue more rapidly compared to prior business models."

About MedClean Technologies, Inc.

MedClean Technologies, Inc. is a provider of innovative technology and services for the onsite treatment and disposal of regulated medical waste. MedClean's flagship MedClean(R) Series systems are fully integrated, turnkey technology solutions that enable hospitals and other healthcare providers to safely, efficiently and cost-effectively convert bio-hazardous regulated medical waste into sterile, unrecognizable material suitable for disposal as municipal solid waste. MedClean was founded in 1997 with corporate headquarters, research and development and distribution facilities located in Bethel, Connecticut. Further information on MedClean can be found at http://www.medcleantechnologies.com and in filings with the Securities and Exchange Commission found at http://www.sec.gov.

Statements about our future expectations are "forward-looking statements" within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. When used herein, the words "may," "will," "should," "anticipate," "believe," "appear," "intend," "plan," "expect," "estimate," "approximate," and similar expressions are intended to identify such forward-looking statements. These statements involve risks and uncertainties inherent in our business, including those set forth in our most recent Annual Report on Form 10-K for the year ended December 31, 2007, filed with the SEC on March 31, 2008, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.



     Contacts:
     MedClean Technologies, Inc.            Investor Contact:
     Kevin Dunphy                           Cameron Donahue
     Chief Financial Officer                Hayden IR
     (203) 798-1080                         (651) 653-1854
     kdunphy@aduromed.com                   cameron@haydenir.com

SOURCE MedClean Technologies, Inc.